Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus Assay) to detect multidrug-resistant tuberculosis

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1559-1566

  Kipiani, Maia ^a   Mirtskhulava, Veriko ^a   Tukvadze, Nestani ^a   Magee, Matthew ^b,c   Blumberg, Henry M ^c,d   Kempker, Russell R ^d  

^a Georgia   (Georgia)

^b GEORGIA STATE UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical outcomes; Drug resistance; MTBDRplus; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW UP; GENOTYPE MTBDR PLUS ASSAY; GENOTYPING TECHNIQUE; HUMAN; INFECTION CONTROL; INTERVENTION STUDY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; TUBERCULOSIS RAPID TEST; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84924413166     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu631     Document Type: Article

References (21)

1. WHO. Global Tuberculosis Report 2013. WHO/HTM/20131.
2. Gegia M, Kalandadze I, Kempker RR, Magee MJ, Blumberg HM. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2012; 16: e391-6.
3. Tukvadze N, Kempker RR, Kalandadze I, et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 2012; 7: e31563.
4. WHO. Policy Statement: Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. 2008.
5. WHO. Policy statement: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/TB/2011.4.
6. Steingart KR, Sohn H, Schiller I, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1: CD009593.
7. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: A meta-analysis. BMC Infect Dis 2009; 9: 67.
8. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better tests, better care: Improved diagnostics for infectious diseases. Clin Infect Dis 2013; 57(Suppl. 3): S139-70.
9. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis 2004; 38: 1586-91.
10. Parsons LM, Somoskovi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: Challenges and opportunities. Clin Microbiol Rev 2011; 24: 314-50.
11. Genotype MTBDRplus, product page. Available at: http://www.hainlifescience.de/en/products/microbiology/mycobacteria/genotypemtbdrplus.html. Nehren, Germany: Hain Lifescience. Accessed 1 December 2013.
12. Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time-to-event data. In: Model development. 2nd ed. Wiley-Interscience, 2008.
13. Shenoi SV, Escombe AR, Friedland G. Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis 2010; 50(Suppl. 3): S231-7.
14. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G, Golub JE. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: An observational cohort study. PLoS One 2012; 7: e49898.
15. Jacobson KR, Theron D, Kendall EA, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013; 56: 503-8.
16. Kurbatova EV, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 1335-43.
17. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One 2009; 4: e6914.
18. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: Time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-39.
19. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drugresistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010; 14: 1233-43.
20. Gandhi NR, Weissman D, Moodley P, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis 2013; 207: 9-17.
21. Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: Systematic review and meta-analysis. Clin Infect Dis 2014; 58: 381-91.